Don’t prescribe or dispense benzodiazepines without building a discontinuation strategy into the patient’s treatment plan (except for patients who have a valid indication for long-term use).

Benzodiazepines are commonly prescribed drugs in Canada for anxiety disorders and insomnia. Strong evidence shows that long-term use of benzodiazepines in elderly patients is associated with tolerance, dependence and adverse effects, including sedation, impaired memory and cognition, falls, hip fractures, depression and increased hospital admissions. Prescribing guidelines recommend exploring alternative non-pharmacological and pharmacological options prior to prescribing benzodiazepines. If determined to be beneficial for the patient, benzodiazepines should not usually be prescribed for long-term use and discontinuation strategies should be built into the patient’s treatment plan, such as gradual dose tapering, cognitive-behavioural therapy and alternative or tapering medications.

 

Sources:

Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry. 2005 May;18(3):249-55. PMID: 16639148.

Baillargeon L, et al. Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial. CMAJ. 2003;169(10):1015-20. PMID: 14609970.

Chang F. Strategies for benzodiazepine withdrawal in seniors: Weaning patients off these medications is a challenge. Can Pharm J. 2005 Nov 1; 138(8):38-40.

Chen L, et al. Discontinuing benzodiazepine therapy: An interdisciplinary approach at a geriatric day hospital. Can Pharm J. 2010 Nov 1;143(6):286-95.

Gallagher HC. Addressing the issue of chronic, inappropriate benzodiazepine use: how can pharmacists play a role? Pharmacy. 2013;1(2):65-93.

Glass J, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits.

BMJ. 2005 Nov 19;331(7526):1169. PMID: 16284208.

National Pain Centre. The 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain [Internet]. 2017 [cited 2017 Aug 18].

Pollmann A, et al. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol. 2015 Jul 4;16:19. PMID: 26141716.

Pottie K, et al. Evidence-based clinical practice guideline for deprescribing benzodiazepine receptor agonists. Unpublished manuscript [Internet]. 2016 Mar (cited 2017 Jun 26).